Previous 10 | Next 10 |
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2020 Results Conference Call November 04, 2020 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participa...
Pieris Pharmaceuticals (PIRS) Q3 net loss was $14.3M or EPS of$0.26, misses consensus by $0.13. This compares to a net loss of $2.6M or EPS loss of $0.05.G&A expense were $4.1M, compared to $4.8M.R&D expenses were $11.8M, compared to $13.2M.Cash, cash equivalents, and investments...
Pieris Pharmaceuticals (PIRS): Q3 GAAP EPS of -$0.26 misses by $0.13.Revenue of $2.94M (-80.6% Y/Y) misses by $8.78M.Press Release For further details see: Pieris Pharmaceuticals EPS misses by $0.13, misses on revenue
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST PRS-060/AZD1402 first regulatory submission for global phase 2a study has been made; site initiation and patient screening expected this year PRS-343 in-use studies requested by FDA are complete...
Biotech Penny Stocks To Watch Right Now With Recent & Upcoming Developments The countdown has begun and penny stocks are already part of the conversation for this week. The next few days could determine a lot not only for the U.S. but for the future of certain policymaking. As I...
BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announ...
The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this event. For further details see: Pieris Pharmaceuticals (PIRS) Presents at ESMO Virtual Congress - Slideshow
Gainers: Cubic (CUB) +30%.AcelRx Pharmaceuticals (ACRX) +23%.VerifyMe (VRME) +22%.Cardiff Oncology (CRDF) +19%.Roku (ROKU) +16%.Trinity Place (TPHS) +14%.Super League Gaming (SLGG) +12%.Humanigen (HGEN) +12%.CleanSpark (CLSK) +12%.MicroVision (MVIS) +11%.Losers: Condor Hospitality T...
Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biot...
Clinical benefit in both trials, including one confirmed complete response and three partial responses in the monotherapy trial and four confirmed partial responses in the atezolizumab combination trial Robust durability of response in both trials, including more than 18 months in the...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...